Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials

Aim To evaluate the effect of bempedoic acid on glycaemic and lipid variables in patients with hypercholesterolaemia. Methods A patient‐level pooled analysis of four phase 3, randomized, double‐blind, placebo‐controlled trials evaluated changes in glycaemia, change from baseline in LDL‐C, and advers...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2022-05, Vol.24 (5), p.868-880
Main Authors: Leiter, Lawrence A., Banach, Maciej, Catapano, Alberico L., Duell, P. Barton, Gotto, Antonio M., Laufs, Ulrich, Mancini, G. B. John, Ray, Kausik K., Hanselman, Jeffrey C., Ye, Zhan, Bays, Harold E.
Format: Article
Language:English
Subjects:
Acids
Blood glucose
cardiovascular disease
Cholesterol, LDL
Clinical outcomes
Clinical trials
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Dicarboxylic Acids
Double-Blind Method
Fatty Acids
Glycemic Control
Humans
Hypercholesterolemia
lipid‐lowering therapy
Low density lipoprotein
Metabolic syndrome
Original
Patients
Placebos
Prediabetic State - complications
Prediabetic State - drug therapy
Statins
Treatment Outcome
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To evaluate the effect of bempedoic acid on glycaemic and lipid variables in patients with hypercholesterolaemia. Methods A patient‐level pooled analysis of four phase 3, randomized, double‐blind, placebo‐controlled trials evaluated changes in glycaemia, change from baseline in LDL‐C, and adverse events. Patients (N = 3621) on maximally tolerated statins were randomized 2:1 to oral bempedoic acid 180 mg or placebo once daily for 12 to 52 weeks with the results analysed by baseline glycaemic status (diabetes, prediabetes, or normoglycaemia). Results The annual rate of new‐onset diabetes for bempedoic acid versus placebo in patients with normoglycaemia at baseline (n = 618) was 0.3% versus 0.8%, and for patients with prediabetes at baseline (n = 1868) it was 4.7% versus 5.9%. In patients with diabetes or prediabetes, bempedoic acid significantly (P 
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.14645